Sigyn Therapeutics, Inc.
SIGY
$2.75
$0.2610.44%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 39.93% | -36.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.25% | -40.88% | |||
| Operating Income | -14.25% | 40.88% | |||
| Income Before Tax | -27.89% | 56.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -27.89% | 56.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -27.89% | 56.32% | |||
| EBIT | -14.25% | 40.88% | |||
| EBITDA | -14.29% | 40.95% | |||
| EPS Basic | -26.83% | 65.19% | |||
| Normalized Basic EPS | -18.05% | 62.60% | |||
| EPS Diluted | -26.47% | 64.80% | |||
| Normalized Diluted EPS | -18.05% | 62.60% | |||
| Average Basic Shares Outstanding | 0.84% | 25.48% | |||
| Average Diluted Shares Outstanding | 0.84% | 25.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||